Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
FDA hits pause on another of PepGen's muscular dystrophy trials
The CONNECT2-EDO51 trial is designed to test PepGen’s PGN-EDO51 exon-skipping therapy over 25 weeks in patients with DMD.
James Waldron
Dec 16, 2024 9:45am
Novartis signs $1.1B deal for muscular dystrophy biotech
Nov 21, 2024 8:19am
Regenxbio starts pivotal study for DMD gene therapy
Nov 18, 2024 2:24pm
Sarepta axes late-phase DMD drug over safety signal, FDA talks
Nov 7, 2024 7:45am
Wave surfs DMD success to regulators' doors, sending stock up
Sep 24, 2024 9:51am
Capricor sells Europe rights to late-stage DMD therapy for $35M
Sep 18, 2024 5:55am
